# US 2024/0390706 A1 · Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390706 A1
- Document ID: US20240390706A1
- Status: Published application
- Kind: A1
- Application number: 18/796,697
- Filed: 2024-08-07
- Published: 2024-11-28
- Earliest claimed: 2018-05-02
- Assignees: The U.S.A., as represented by the Secretary, Department of Health and Human Services; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Inventors: Masaru Kanekiyo; Michael Gordon Joyce; Wei Bu; Jeffrey I. Cohen; Yaroslav Tsybovsky
- Web page: https://patentgrep.com/patent/US20240390706A1

## CPC

- A61K 47/6839: {the antibody targeting material from viruses}
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61P 31/22: for herpes viruses
- C07K 16/085: Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
- C12Q 1/705: {for herpetoviridae, e.g. herpes simplex, varicella zoster}
- G01N 33/56994: {Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/55: Fab or Fab'
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12Q 2600/158: Expression markers
- G01N 2333/05: Epstein-Barr virus
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Anti-EBV gH antibodies, anti-EBV gL antibodies, anti-EBV gH/gL antibodies, and compositions of matter useful for the detection, diagnosis, prevention, and treatment of Epstein Barr Virus infection in humans, and methods of using those compositions of matter for the same.

## Claims

### Claim 1

An isolated nucleic acid having a nucleotide sequence that encodes a monoclonal antibody comprising:
a) heavy chain (h) complementary determining region (CDR) 1, CDR2 and CDR3 sequences from a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 21, SEQ ID NO: 31, SEQ ID NO: 41, SEQ ID NO: 51, SEQ ID NO: 61, SEQ ID NO: 71, SEQ ID NO: 81, SEQ ID NO: 91, SEQ ID NO: 101, SEQ ID NO: 111, SEQ ID NO: 121, SEQ ID NO: 131, SEQ ID NO: 141, SEQ ID NO: 151, SEQ ID NO: 161, SEQ ID NO: 171, SEQ ID NO: 181, and SEQ ID NO: 191; and,
b) light chain (1) CDR1, CDR2 and CDR3 sequences from a sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 16, SEQ ID NO: 26, SEQ ID NO: 36, SEQ ID NO: 46, SEQ ID NO: 56, SEQ ID NO: 66, SEQ ID NO: 76, SEQ ID NO: 86, SEQ ID NO: 96, SEQ ID NO: 106, SEQ ID NO: 116, SEQ ID NO: 126, SEQ ID NO: 136, SEQ ID NO: 146, SEQ ID NO: 156, SEQ ID NO: 166, SEQ ID NO: 176, SEQ ID NO: 186, and SEQ ID NO: 196;
wherein the monoclonal antibody binds an Epstein Barr Virus (EBV) gH protein (gH), an EBV gL protein (gL), or a gH/gL protein complex.

### Claim 2 (depends on 1)

The isolated nucleic acid of claim 1, wherein the monoclonal antibody, comprises
(a) a complementary determining region (CDR)-heavy 1 (h1) sequence of any one of SEQ ID NO:3, SEQ ID NO: 13, SEQ ID NO:23, SEQ ID NO:33, SEQ ID NO:43, SEQ ID NO: 53, SEQ ID NO:63, SEQ ID NO: 73, SEQ ID NO:83, SEQ ID NO:93, SEQ ID NO: 103, SEQ ID NO:113, SEQ ID NO: 123, SEQ ID NO:133, SEQ ID NO:143, SEQ ID NO: 153, SEQ ID NO: 163, SEQ ID NO: 173, SEQ ID NO: 183, or SEQ ID NO: 193;
(b) a CDR-heavy 2 (h2) sequence of any one of SEQ ID NO:4, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:34, SEQ ID NO:44, SEQ ID NO:54, SEQ ID NO:64, SEQ ID NO: 74, SEQ ID NO:84, SEQ ID NO:94, SEQ ID NO: 104, SEQ ID NO: 114, SEQ ID NO: 124, SEQ ID NO:134, SEQ ID NO: 144, SEQ ID NO: 154, SEQ ID NO: 164, SEQ ID NO: 174, SEQ ID NO: 184, or SEQ ID NO: 194;
(c) a CDR-heavy 3 (h3) sequence of any one of SEQ ID NO:5, SEQ ID NO:15, SEQ ID NO:25, SEQ ID NO:35, SEQ ID NO:45, SEQ ID NO:55, SEQ ID NO:65, SEQ ID NO: 75, SEQ ID NO:85, SEQ ID NO:95, SEQ ID NO: 105, SEQ ID NO: 115, SEQ ID NO: 125, SEQ ID NO: 135, SEQ ID NO: 145, SEQ ID NO: 155, SEQ ID NO: 165, SEQ ID NO: 175, SEQ ID NO:185, or SEQ ID NO:195;
(d) a CDR-light 1 (11) sequence of any one of SEQ ID NO:8, SEQ ID NO:18, SEQ ID NO:28, SEQ ID NO:38, SEQ ID NO:48, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO: 78, SEQ ID NO:88, SEQ ID NO:98, SEQ ID NO: 108, SEQ ID NO: 118, SEQ ID NO: 128, SEQ ID NO: 138, SEQ ID NO: 148, SEQ ID NO: 158, SEQ ID NO: 168, SEQ ID NO: 178, SEQ ID NO:188, or SEQ ID NO:198;
(c) a CDR-light 2 (12) sequence of any one of SEQ ID NO:9, SEQ ID NO: 19, SEQ ID NO:29, SEQ ID NO:39, SEQ ID NO:49, SEQ ID NO:59, SEQ ID NO:69, SEQ ID NO: 79, SEQ ID NO:89, SEQ ID NO:99, SEQ ID NO: 109, SEQ ID NO:119, SEQ ID NO: 129, SEQ ID NO: 139, SEQ ID NO: 149, SEQ ID NO: 159, SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, or SEQ ID NO: 199; and
(f) a CDR-light 3 (13) sequence of any one of SEQ ID NO:10, SEQ ID NO:20, SEQ ID NO:30, SEQ ID NO:40, SEQ ID NO:50, SEQ ID NO:60, SEQ ID NO:70, SEQ ID NO: 80, SEQ ID NO:90, SEQ ID NO: 100, SEQ ID NO: 110, SEQ ID NO: 120, SEQ ID NO: 130, SEQ ID NO: 140, SEQ ID NO:150, SEQ ID NO: 160, SEQ ID NO:170, SEQ ID NO: 180, SEQ ID NO: 190, or SEQ ID NO:200.

### Claim 3 (depends on 1)

The isolated nucleic acid of claim 1, wherein the monoclonal antibody comprises:
the VH sequence of SEQ ID NO: 1 and a VL sequence of SEQ ID NO:6;
the VH sequence of SEQ ID NO:11 and a VL sequence of SEQ ID NO: 16;
the VH sequence of SEQ ID NO:21 and a VL sequence of SEQ ID NO:26;
the VH sequence of SEQ ID NO:31 and a VL sequence of SEQ ID NO:36;
the VH sequence of SEQ ID NO:41 and a VL sequence of SEQ ID NO:46;
the VH sequence of SEQ ID NO:51 and a VL sequence of SEQ ID NO:56;
the VH sequence of SEQ ID NO:61 and a VL sequence of SEQ ID NO:66;
the VH sequence of SEQ ID NO:71 and a VL sequence of SEQ ID NO:76;
the VH sequence of SEQ ID NO:81 and a VL sequence of SEQ ID NO:86;
the VH sequence of SEQ ID NO:91 and a VL sequence of SEQ ID NO:96;
the VH sequence of SEQ ID NO: 101 and a VL sequence of SEQ ID NO: 106;
the VH sequence of SEQ ID NO:111 and a VL sequence of SEQ ID NO: 116;
the VH sequence of SEQ ID NO: 121 and a VL sequence of SEQ ID NO: 126;
the VH sequence of SEQ ID NO: 131 and a VL sequence of SEQ ID NO:136;
the VH sequence of SEQ ID NO: 141 and a VL sequence of SEQ ID NO: 146;
the VH sequence of SEQ ID NO:151 and a VL sequence of SEQ ID NO:156;
the VH sequence of SEQ ID NO:161 and a VL sequence of SEQ ID NO:166;
the VH sequence of SEQ ID NO: 171 and a VL sequence of SEQ ID NO:176;
the VH sequence of SEQ ID NO:181 and a VL sequence of SEQ ID NO: 186; or
the VH sequence of SEQ ID NO: 191 and a VL sequence of SEQ ID NO: 196.

### Claim 4 (depends on 1)

An expression vector comprising the nucleic acid of claim 1 operably linked to control sequences recognized by a host cell transformed with the vector.

### Claim 5 (depends on 4)

A host cell comprising the expression vector of claim 4.

### Claim 6 (depends on 5)

The host cell of claim 5, wherein the cell is a mammalian cell, a bacterial cell, an insect cell, or a yeast cell.

### Claim 7 (depends on 6)

A process for producing a monoclonal antibody, comprising:
culturing the host cell of claim 6 under conditions suitable for expression of the monoclonal antibody; and
recovering the monoclonal antibody from the cell culture.

### Claim 8 (depends on 1)

The isolated nucleic acid of claim 1, wherein the VH domain of the monoclonal antibody and the VL domain of the monoclonal antibody are respectively encoded by:
(a) SEQ ID NO: 2 and SEQ ID NO: 7;
(b) SEQ ID NO: 12 and SEQ ID NO: 17;
(c) SEQ ID NO: 22 and SEQ ID NO: 27;
(d) SEQ ID NO: 32 and SEQ ID NO: 37;
(e) SEQ ID NO: 42 and SEQ ID NO: 47;
(f) SEQ ID NO: 52 and SEQ ID NO: 57;
(g) SEQ ID NO: 62 and SEQ ID NO: 67;
(h) SEQ ID NO: 72 and SEQ ID NO: 77;
(i) SEQ ID NO: 82 and SEQ ID NO: 87;
(j) SEQ ID NO: 92 and SEQ ID NO: 97;
(k) SEQ ID NO: 102 and SEQ ID NO: 107;
(l) SEQ ID NO: 112 and SEQ ID NO: 117;
(m) SEQ ID NO: 122 and SEQ ID NO: 127;
(n) SEQ ID NO: 132 and SEQ ID NO: 137;
(o) SEQ ID NO: 142 and SEQ ID NO: 147;
(p) SEQ ID NO: 152 and SEQ ID NO: 157;
(q) SEQ ID NO: 162 and SEQ ID NO: 167;
(r) SEQ ID NO: 172 and SEQ ID NO: 177;
(s) SEQ ID NO: 182 and SEQ ID NO: 187; or
(t) SEQ ID NO: 192 and SEQ ID NO: 197.

### Claim 9 (depends on 1)

The isolated nucleic acid of claim 1, where the monoclonal antibody is an antibody fragment.

### Claim 10 (depends on 1)

The isolated nucleic acid of claim 1, where the monoclonal antibody is a chimeric antibody.

### Claim 11 (depends on 1)

The isolated nucleic acid of claim 1, where the monoclonal antibody is a bispecific antibody.

### Claim 12 (depends on 1)

A method of inhibiting the growth of a cell that expresses an EBV gH protein, an EBV gL protein, or an EBV gH/gL complex, comprising infecting the cell with the isolated nucleic acid of claim 1, wherein the binding of the monoclonal antibody encoded by the isolated nucleic acid to the EBV gH protein, the EBV gL protein or the EBV gH/gL complex causes an inhibition of growth of the cell.

### Claim 13 (depends on 1)

A method of inhibiting EBV in an individual having an EBV infection, including an EBV-associated disease or disorder, comprising administering to the individual an effective amount of the isolated nucleic antibody of claim 1.

### Claim 14 (depends on 13)

The method of claim 13, wherein the individual is a human.

### Claim 15 (depends on 1)

A method of inhibiting Epstein-Barr virus (EBV) infection in a subject, comprising administering to the subject an effective amount of the isolated nucleic acid of claim 1.

### Claim 16 (depends on 15)

The method of claim 15, wherein the subject is a human.
